2CV Stock Overview
Engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
ConvaTec Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.68 |
| 52 Week High | UK£3.44 |
| 52 Week Low | UK£2.52 |
| Beta | 0.63 |
| 1 Month Change | -5.63% |
| 3 Month Change | 2.29% |
| 1 Year Change | -5.63% |
| 3 Year Change | 20.72% |
| 5 Year Change | 17.03% |
| Change since IPO | 8.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2CV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -2.9% | -2.6% |
| 1Y | -5.6% | -8.5% | 6.9% |
Return vs Industry: 2CV exceeded the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 2CV underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 2CV volatility | |
|---|---|
| 2CV Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2CV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2CV's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,000 | Karim Bitar | www.convatecgroup.com |
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
ConvaTec Group PLC Fundamentals Summary
| 2CV fundamental statistics | |
|---|---|
| Market cap | €5.45b |
| Earnings (TTM) | €146.83m |
| Revenue (TTM) | €2.11b |
37.1x
P/E Ratio2.6x
P/S RatioIs 2CV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2CV income statement (TTM) | |
|---|---|
| Revenue | US$2.20b |
| Cost of Revenue | US$970.50m |
| Gross Profit | US$1.23b |
| Other Expenses | US$1.08b |
| Earnings | US$153.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 0.075 |
| Gross Margin | 55.89% |
| Net Profit Margin | 6.96% |
| Debt/Equity Ratio | 80.4% |
How did 2CV perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield84%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ConvaTec Group PLC is covered by 34 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hassan Al-Wakeel | Barclays |
| Samuel England | Berenberg |
| Marianne Bulot | BofA Global Research |